Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
XPC-4
- Development stage
- Preclinical
- Lead developer
- Xenon Pharmaceuticals
- Modality
- Small Molecules
01
Overview
XPC-4 is a preclinical-stage small molecule inhibitor of the voltage-gated sodium channel NaV1.7 (SCN9A), developed by Xenon Pharmaceuticals. It serves as a representative research compound comparable to Xenon's clinical candidate XEN1701. In preclinical studies in cynomolgus monkeys, doses of XPC-4 achieving greater than 75% NaV1.7 receptor occupancy demonstrated significant reductions in capsaicin-evoked heat pain (approximately 85% to 100% reduction at the highest doses tested) without causing clinically meaningful changes in systolic blood pressure or heart rate. XPC-4 is utilized to support the development of non-opioid therapeutic strategies for the treatment of acute and chronic pain.
02
Targets
SCN9A (Sodium channel protein type 9 subunit alpha)
Beyond the preview
Go deeper on XPC-4.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on XPC-4.